Goodbye IMI, Hello IHI: New EU Partnership Prepares To Invite Research Proposals

Broadened Membership Includes Medtech & Digital Health

The new iteration of the EU’s successful public-private R&D partnership will seek to integrate pharmaceutical research with medical technology and digital health platforms to produce innovative cross-sectoral projects in areas such as drug/device combinations and AI-based diagnostics.

Doctor and robot shaking hands over stethoscope
The use of AI in pharmaceutical research is on the rise. • Source: Alamy

The EU’s new public-private partnership, the Innovative Health Initiative (IHI), a more broad-based and cross-sectoral successor to the long-running Innovative Medicines Initiative (IMI), says it expects to launch its first call for research proposals during the first half of 2022.

While the IMI brought together the European Commission and the European pharmaceutical industry federation EFPIA, the IHI is a new...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Europe

UK HRA Working On ‘Trusted’ Path Forward To Support Simplified Informed Consent

 
• By 

The Health Research Authority is working on a streamlined model for informed consent that maintains people’s trust.

EU Ups Ante On Stockpiling For Crises

 

The European Commission has published two new strategies on stockpiling that will improve the availability of critical medicines in times of crisis and reduce the EU’s dependance on suppliers outside the bloc.

‘Seize the Moment:’ European Drug Regulators Called To Act On Changes In US

 

European regulators must work hard to maintain and build vital but fragile trust in science and processes, said speakers at an event celebrating the European Medicines Agency 30th anniversary.

EMA’s PRIME Scheme Explored: Growing Designations - But Are Accelerated Assessments Slipping?

 

While the first six months of the year saw eight new drugs targeting a range of diseases enter the European Medicines Agency’s priority medicines scheme, and three PRIME-designated treatments go on to win EU marketing approval, use of the accelerated assessment mechanism appears to be limited.

More from Geography

UK HRA Working On ‘Trusted’ Path Forward To Support Simplified Informed Consent

 
• By 

The Health Research Authority is working on a streamlined model for informed consent that maintains people’s trust.

EU Ups Ante On Stockpiling For Crises

 

The European Commission has published two new strategies on stockpiling that will improve the availability of critical medicines in times of crisis and reduce the EU’s dependance on suppliers outside the bloc.

‘Seize the Moment:’ European Drug Regulators Called To Act On Changes In US

 

European regulators must work hard to maintain and build vital but fragile trust in science and processes, said speakers at an event celebrating the European Medicines Agency 30th anniversary.